ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

Leukemia & Lymphoma

LLS Precision Medicine Trial May Change Treatment Paradigm for AML Patients

The Leukemia & Lymphoma Society will head up the Beat AML Master Trial, which will use a precision medicine protocol under the support and guidance from the FDA. Image © Minerva Studio/Shutterstock.com 

Leukemia & Lymphoma

Researchers have discovered a three-drug combo that may combat acute lymphoblastic leukemia by shutting down the production of nucleotides that activate a DNA replication stress response.

Natural killer cells derived from donated umbilical cords could be modified to seek and destroy some types of leukemia and lymphoma.

The FDA has approved inotuzumab ozogamicin (Besponsa) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Acalabrutinib has been granted FDA Breakthrough Therapy Designation for the treatment of patients with mantle cell lymphoma who have relapsed or have received at least one prior therapy.

A large genomic sequencing analysis of patients with T-ALL revealed a new landscape of mutations that may inform future treatment strategies.

Researchers have identified two distinct stem cell–like populations from which relapse can arise in AML patients, which may help clinicians identify who will and won't respond to standard chemotherapy.

ODAC approval of Novartis' CAR T-Cell therapy paves the way for its FDA approval as a commercially available treatment for B-cell ALL.

Pages

Subscribe to Leukemia & Lymphoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.